RUBICON vs SAKAR: Stock Comparison
RUBICON RESEARCH is the larger company by market capitalisation. RUBICON RESEARCH shows a higher ROE, a higher dividend yield and faster revenue growth, while SAKAR HEALTHCARE shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
RUBICON leads 9; SAKAR leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | RUBICON | SAKAR |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | RUBICON | SAKAR |
|---|---|---|
| Live Price | ₹1,791.1 | ₹1,129.7 |
| Day Change | 1.38% | 2.2% |
| Volume | 1.17 L | 49,234 |
| 52-Week High | ₹1,899 | ₹1,211 |
| 52-Week Low | ₹570.75 | ₹345.5 |
| Distance from 52W High | -5.68% | -6.71% |
Valuation
| Metric | RUBICON | SAKAR |
|---|---|---|
| Market Cap | ₹29,632 Cr | ₹2,516 Cr |
| P/E Ratio | 102.12x | 67.2x |
| P/B Ratio | 22.84x | 7.47x |
| EPS | ₹4.99 | ₹4.62 |
| Book Value | ₹77.93 | ₹128.3 |
| Dividend Yield | 0.08% | 0% |
Growth
| Metric | RUBICON | SAKAR |
|---|---|---|
| Revenue Growth (TTM YoY) | 43.5% | 40.1% |
| EPS Growth (TTM YoY) | 96.6% | 87.2% |
| Qtr Sales Growth | -19.95% | 0% |
| Qtr Profit Growth | -2.75% | 0% |
Profitability & Leverage
| Metric | RUBICON | SAKAR |
|---|---|---|
| ROE | 19.14% | 10.68% |
| ROCE | 20.49% | 10.13% |
| Net Margin | 13.48% | 12.11% |
| Operating Margin | 20.68% | 18.91% |
| Debt to Equity | 0.2x | 0.26x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | RUBICON | SAKAR |
|---|---|---|
| Promoter Holding | 23.93%▼ 0.04 pp | 52.52%▼ 0.34 pp |
| FII Holding | 7.52%▼ 0.02 pp | 12.13%▼ 0.81 pp |
| DII Holding | 9.43%▼ 0.59 pp | 11.37%▲ 0.05 pp |
| Public Holding | 23.3%▲ 0.72 pp | 23.98%▲ 1.11 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: RUBICON RESEARCH and SAKAR HEALTHCARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.